Ratings AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Real-time Estimate Cboe BZX Other stock markets 03:48:34 2024-04-19 pm EDT			5-day change	1st Jan Change
6.255 ^USD	+2.21%		-2.12%	-20.47%

Apr. 08	North American Morning Briefing : Inflation Data, -2-	DJ
Apr. 05	Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
ANGIODYNAMICS, INC.	-21.94%	245M	C
ABBOTT LABORATORIES	-4.36%	183B	C+
MEDTRONIC PLC	-3.87%	105B	C
BECTON, DICKINSON AND COMPANY	-4.38%	67.36B	A
DEXCOM, INC.	+8.23%	51.77B	B-
CENCORA, INC.	+15.54%	47.29B	B-
HOYA CORPORATION	-1.73%	40.2B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+7.16%	27.62B	A-
SARTORIUS STEDIM BIOTECH	-16.58%	21.75B	B
METTLER-TOLEDO INTERNATIONAL, INC.	-1.68%	25.51B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes